Correction: Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis

Eric Balti¹, Sarah Verhaeghe¹, Vibeke Kruse^{2

3

4}, Stijn Roels⁵, Peter Coremans¹

Affiliations

¹ Department of Endocrinology and Diabetes, VITAZ Hospital, Sint-Niklaas, BEL.
² Department of Medical Oncology, VITAZ Hospital, Sint-Niklaas, BEL.
³ Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), University of Antwerp, Wilrijk, BEL.
⁴ Department of Oncology, Antwerp University Hospital, Edegem, BEL.
⁵ Department of Radiology, VITAZ Hospital, Sint-Niklaas, BEL.

Published Erratum

Eric Balti et al. Cureus. 2024.

. 2024 Mar 20;16(3):c166.

doi: 10.7759/cureus.c166. eCollection 2024 Mar.

Eric Balti¹, Sarah Verhaeghe¹, Vibeke Kruse^{2

3

4}, Stijn Roels⁵, Peter Coremans¹

¹ Department of Endocrinology and Diabetes, VITAZ Hospital, Sint-Niklaas, BEL.
² Department of Medical Oncology, VITAZ Hospital, Sint-Niklaas, BEL.
³ Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), University of Antwerp, Wilrijk, BEL.
⁴ Department of Oncology, Antwerp University Hospital, Edegem, BEL.
⁵ Department of Radiology, VITAZ Hospital, Sint-Niklaas, BEL.

Abstract

[This corrects the article DOI: 10.7759/cureus.27763.].

No competing interests declared.

Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis.
Balti E, Verhaeghe S, Kruse V, Roels S, Coremans P. Balti E, et al. Cureus. 2022 Aug 7;14(8):e27763. doi: 10.7759/cureus.27763. eCollection 2022 Aug. Cureus. 2022. PMID: 36127991 Free PMC article.